19 May 2026

New evidence for pharmacology for coronary artery disease

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Anchorperson: D. Capodanno

Spokesperson: J. Silvain

Summary

This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus aspirin, providing a thorough update on optimizing medical therapy in coronary patients.

Presentations available when logged in:

Evolocumab in patients with coronary stenting and no prior myocardial infarction: results from the VESALIUS-CV trial
Early aspirin cessation after PCI in AMI: stratification by ischemic risk from TARGET FIRST trial
Aspirin-free strategy after complex PCI in ACS: the NEO-MINDSET COMPLEX subanalysis
Net outcomes of clopidogrel vs. aspirin after coronary stenting by bleeding risk and PCI complexity

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

New evidence for pharmacology for coronary artery disease

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Log in or create account for free